Biodesix Presents Numerous Research Findings at ATS, ASCO, and AACR Virtual Conferences
Clinical Data Offer Meaningful Diagnostic Information for Patients in the Lung Cancer Continuum of Care
BOULDER, Colo.–(BUSINESS WIRE)–Biodesix, Inc., a leading diagnostic company in lung disease, recently published three clinical research abstracts, which reported valuable new information regarding treatment of patients in the lung cancer continuum of care. The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO), and American Association for Cancer Research (AACR).
Abstract #A4465: First Look at the Distribution of Risk of Malignancy Pre and Post-Test Using a Blood-Based Biomarker in Patients with Pulmonary Nodules in a Real-World Observational Study
Published: ATS, American Journal of Respiratory and Critical Care Medicine, May 1
An abstract published by Michael Pritchett, DO, MPH of Pinehurst Medical Clinic reports findings from the ORACLE observational study (NCT03766958), which highlights the use of the Nodify XL2 test. The data suggest that using blood-based biomarkers integrated with clinical risk factors to calculate risk of malignancy for solitary pulmonary nodules may be important in helping guide physicians in determining treatment strategy, including potentially reducing performance of invasive procedures on benign nodules. Dr. Pritchett will present the data in a webinar on June 18.
Abstract #9545: Real-World Performance of Blood-Based Host Immune Profiling in First-line Immunotherapy Treatment in Advanced Stage Non-Small Cell Lung Cancer
Published: ASCO Virtual Annual Meeting, Journal of Clinical Oncology, May 13
An abstract published by R. Brian Mitchell, M.D. of Virginia Cancer Institute reports data from the interim analysis of the ongoing INSIGHT clinical study (NCT03289780). The data suggest that blood-based host immune profiling can provide clinically significant information to predict outcomes and guide treatment choices made by physicians for patients with advanced non-small cell lung cancer eligible for immune checkpoint inhibitor therapy. This abstract will be available as an e-poster at ASCO’s upcoming annual meeting. Wallace Akerley, M.D. of Huntsman Cancer Institute will present the data in a webinar on June 3.
Abstract # 3101 / 11: Utility of a New Targeted Next Generation Sequencing Test for Liquid Biopsy Samples from Patients with NSCLC
Published: AACR Virtual Annual Meeting II, May 15
In an abstract published by Hestia Mellert, Ph.D., of Biodesix, data suggest that a newly-developed blood-based next generation sequencing test method supports the usefulness of molecular detection of actionable and emerging biomarkers in a liquid biopsy. The abstract will be available as an e-poster at AACR’s Virtual Annual Meeting II. Dr. Mellert will present the data from the poster in a webinar on June 25.
“Acceptance of these abstracts, especially at three of the most important events in oncology and pulmonology, is extremely meaningful for Biodesix. It is a testament to the value of our research, and our commitment to delivering actionable results,” said Scott Hutton, Chief Executive Officer of Biodesix. “The data presented in these abstracts represent another step for Biodesix in solving complex diagnostic challenges in lung disease, and we’re tremendously proud to share that.”
Biodesix is a leading diagnostic company with a focus in lung disease. The Company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. Biodesix is the first company to offer six non-invasive tests for patients with diseases of the lung. Biodesix launched the SARS-CoV-2 ddPCR™ test and the Platelia SARS-CoV-2 Total Ab in response to the global pandemic and virus that impacts the lung and causes COVID-19. The blood-based Biodesix Lung Reflex® strategy for lung cancer patients integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours, expediting time to treatment. The blood-based Nodify Lung™ nodule risk assessment testing strategy consisting of the Nodify XL2™ test and the Nodify CDT™ test evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. Biodesix also collaborates with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. For more information about Biodesix, please visit www.biodesix.com.
Note Regarding Forward-Looking Statements
This press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical fact, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. Such statements are based on management’s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. Biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. These forward-looking statements are subject to a number of risks, uncertainties and assumptions. Moreover, Biodesix operates in a competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for its management to predict all risks, nor can it assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. Biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement.
Jordona Jackson Smith for Biodesix